» Articles » PMID: 23335087

Cancer Statistics, 2013

Overview
Publisher Wiley
Specialty Oncology
Date 2013 Jan 22
PMID 23335087
Citations 6222
Authors
Affiliations
Soon will be listed here.
Abstract

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. A total of 1,660,290 new cancer cases and 580,350 cancer deaths are projected to occur in the United States in 2013. During the most recent 5 years for which there are data (2005-2009), delay-adjusted cancer incidence rates declined slightly in men (by 0.6% per year) and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.5% per year in women. Overall, cancer death rates have declined 20% from their peak in 1991 (215.1 per 100,000 population) to 2009 (173.1 per 100,000 population). Death rates continue to decline for all 4 major cancer sites (lung, colorectum, breast, and prostate). Over the past 10 years of data (2000-2009), the largest annual declines in death rates were for chronic myeloid leukemia (8.4%), cancers of the stomach (3.1%) and colorectum (3.0%), and non-Hodgkin lymphoma (3.0%). The reduction in overall cancer death rates since 1990 in men and 1991 in women translates to the avoidance of approximately 1.18 million deaths from cancer, with 152,900 of these deaths averted in 2009 alone. Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket and other underserved populations.

Citing Articles

Oncological outcomes of surgical management for T2N0M0 glottic laryngeal squamous cell carcinoma.

Zhou J, Xu C, Zhu X, Yang Y, Zhou L, Gong H World J Otorhinolaryngol Head Neck Surg. 2025; 11(1):29-36.

PMID: 40070502 PMC: 11891284. DOI: 10.1002/wjo2.168.


Role of GPX3+ astrocytes in breast cancer brain metastasis activated by circulating tumor cell exosomes.

Huang G, Xu G, Cao Q, Li S, Li H, Zhang X NPJ Precis Oncol. 2025; 9(1):64.

PMID: 40055530 PMC: 11889224. DOI: 10.1038/s41698-025-00833-9.


Saliva as a Diagnostic Tool for Systemic Diseases-A Narrative Review.

Surdu A, Foia L, Luchian I, Trifan D, Tatarciuc M, Scutariu M Medicina (Kaunas). 2025; 61(2).

PMID: 40005360 PMC: 11857487. DOI: 10.3390/medicina61020243.


Challenges to and considerations of designing cancer prevention trials.

Enserro D, Gunn H, Elsaid M, Duan F, Pugh S J Natl Cancer Inst Monogr. 2025; 2025(68):49-55.

PMID: 39989045 PMC: 11848038. DOI: 10.1093/jncimonographs/lgae044.


Psychological distress among cancer patients in African countries: a systematic review and meta-analysis study.

Kibralew G, Wassie Y, Kelebie M, Rtbey G, Tadesse G, Melkam M BMC Psychol. 2025; 13(1):128.

PMID: 39962603 PMC: 11834563. DOI: 10.1186/s40359-025-02447-z.